Tern Plc Tranche One of Device Authority Fund Raise Now Complete

TERN

Tern Plc (AIM:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that, further to the Company’s announcement of 27 December 2023, Tranche One (“T1”) of the Device Authority Fund Raise has now completed.  Through T1 Device Authority has received US$4.0 million.

A further announcement will be made by Tern Plc in due course upon completion of the Second Tranche (“T2”) of the Device Authority Fund Raise. T2 totals US$3.3 million and is contingent on approval pursuant to the National Security and Investment Act 2021 (“NASI”) and acceptance of the approval by Ten Eleven Ventures.

Unless otherwise stated, defined terms should be given the meaning given to them in the announcement made on 27 December 2023.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Fundamental XR builds case for wider surgical simulation adoption

Fundamental XR is expanding the role of virtual simulation in surgical training as hospitals integrate the technology into structured education programmes.

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Search